CollPlant Biotechnologies (CLGN) to Release Earnings on Wednesday

CollPlant Biotechnologies (NASDAQ:CLGN) is projected to issue its Q3 2025 results before the market opens on Wednesday, November 26th. Analysts expect CollPlant Biotechnologies to post earnings of $0.38 per share and revenue of $16.5220 million for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 26, 2025 at 10:00 AM ET.

CollPlant Biotechnologies (NASDAQ:CLGN) last posted its quarterly earnings data on Wednesday, August 20th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of $0.29 by ($0.57). CollPlant Biotechnologies had a negative return on equity of 94.08% and a negative net margin of 541.34%.The firm had revenue of $0.18 million for the quarter, compared to analysts’ expectations of $8.91 million. On average, analysts expect CollPlant Biotechnologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CollPlant Biotechnologies Price Performance

Shares of CollPlant Biotechnologies stock opened at $2.15 on Wednesday. The stock has a market capitalization of $27.34 million, a P/E ratio of -1.90 and a beta of 1.38. The business has a 50 day simple moving average of $2.36 and a two-hundred day simple moving average of $2.20. CollPlant Biotechnologies has a 12 month low of $1.31 and a 12 month high of $4.98.

Analysts Set New Price Targets

Several research firms recently commented on CLGN. Weiss Ratings reissued a “sell (e+)” rating on shares of CollPlant Biotechnologies in a research note on Wednesday, October 8th. D. Boral Capital reaffirmed a “buy” rating and set a $12.00 target price on shares of CollPlant Biotechnologies in a report on Monday, October 20th. Finally, HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of CollPlant Biotechnologies in a research report on Thursday, August 21st. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $11.50.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.